ICON Announces Clinical Research partnership with DuPage Medical Group
14 Maio 2018 - 8:00AM
Business Wire
Additional PMG Research site locations
enhances ICON’s site and patient engagement capabilities
ICON plc (NASDAQ: ICLR), a global provider of drug development
and commercialisation solutions and services, today announced that
PMG Research, Inc., part of ICON Site and Patient Recruitment, and
DuPage Medical Group of Chicago, Illinois have finalised a Master
Agreement formalising a clinical research partnership. Effective
May 2018, PMG Research will assume the research infrastructure at
the DuPage Medical Group.
The expansion of the PMG Research network enhances ICON’s
ability to increase access and engagement with investigator sites
and patients, helping customers to reduce the overall time and cost
associated with drug development. The addition of DuPage Medical
Group provides investigator and patient access in the greater
Chicago area, while bringing clinical research as a care option to
the communities served.
DuPage Medical Group is the largest independent, multi-specialty
physician group in the Chicagoland area, with practice sites in
more than 100 locations in DuPage, Cook, Grundy, Kane, Kendall and
Will Counties. DuPage Medical Group provides patients with access
to more than 700 physicians in over 50 clinical specialties ranging
from primary care to specialty care in areas such as cardiology and
oncology.
“Enrolling and engaging patients in clinical trials continues to
be one of the biggest challenges within drug development. Our
partnership with DuPage Medical Group extends our ability to help
customers enhance clinical trial feasibility and improve patient
enrolment timelines whilst also giving patients access to a broader
range of care options through clinical trials.” Commented EB
McLindon, Senior Vice President, Site & Patient Recruitment,
ICON. “We are committed to enhancing engagement with sites,
patients and healthcare providers to take significant time and cost
from our customers’ development programmes.”
Dr. Paul Merrick, President of DuPage Medical Group, agrees,
“Through this collaboration, additional communities in Illinois,
along with more of DuPage Medical Group’s patients, will have
increased access to clinical research in a broad range of
therapeutic areas. The integration of clinical research into
patient care as a result of partnerships between healthcare
institutions and clinical research site organisations delivers
additional benefits and innovative solutions to the drug
development process; both patients and healthcare providers will
ultimately see lowered costs and faster time to market for
potentially life-saving medications, vaccines, and medical
devices.”
Dr. Paul Merrick continues, “DuPage Medical Group has
participated in clinical trials and research over the last 13 years
in many specialty areas including dermatology, cardiology,
gastroenterology, spine and otolaryngology. Joining forces with
ICON will allow us to continue to expand access in other areas
including oncology and will play an integral role in advancing the
treatment options available to our patients and the communities we
serve.”
About ICON plc
ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to pharmaceutical,
biotechnology, medical device, and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 97 locations in 38 countries and has
approximately 13,380 employees. Further information is available at
www.iconplc.com
About PMG Research, Inc.
PMG Research, Inc. part of ICON Site & Patient Recruitment,
is an integrated network of clinical research facilities operating
53 clinics in 14 cities in North America. It has conducted over
8,100 research studies for hundreds of pharmaceutical sponsors and
CROs since 1979 and has extensive experience conducting all phases
of trials across all major therapeutic areas with particular
experience in cardiology, dermatology, endocrinology,
gastroenterology, men’s health, neurology, pulmonology,
rheumatology, vaccine, and women’s health trials. Further
information is available at www.pmg-research.com.
About DuPage Medical Group
Founded in 1999, DuPage Medical Group is the largest
independent, multi-specialty physician group with more than 700
physicians in over 100 suburban Chicago locations. DMG is a
patient-centered organisation focused on improving access to
convenient, quality health care using the latest technology and
treatment options. For more information, visit
www.dupagemedicalgroup.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180514005519/en/
ICON plcOlivia PimentaWeber Shandwick44-207 067
0557OPimenta@webershandwick.comorPMG ResearchKristin
Kinlaw1-336-608-3506kkinlaw@pmg-research.comorDuPage Medical
GroupMaria McGowan1-630-545-7640Maria.McGowan@DupageMD.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024